TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28922507

Group type: EXPERIMENTAL
Intervention: High-intensity exercise before learning
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: High-intensity exercise during learning
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: High-intensity exercise after learning
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study: 26002610

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1256

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 1256
Study: 25132778

Group type: EXPERIMENTAL
Intervention: 12-week instructor-led group aerobic exercise program (3 days/week, 10 min warm-up, 40 min exercise, 10 min cool-down, increasing intensity from 50% to 70% HRR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ordinary daily activities (control group)
Number of subjects: 60
Study: 22564148

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg weekly dosing after inadequate response to 40 mg eow dosing
Number of subjects: 349

Group type: COMPARATOR
Intervention: Adalimumab 40 mg eow dosing
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg weekly dosing
Number of subjects: 349
Study: 19104360

Group type: EXPERIMENTAL
Intervention: Interactive prenatal testing decision tool
Number of subjects: 496

Group type: COMPARATOR
Intervention: Control (California Department of Health Services' educational booklet)
Number of subjects: 496
Study: 17198705

Group type: EXPERIMENTAL
Intervention: Conventional GnRH‐agonist and recombinant FSH stimulation (IVO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimally stimulated in vitro maturation (IVM) with recombinant FSH and FF‐MAS (0.1-20 microM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IVM with FF‐MAS (20 microM) for 36 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IVM with FF‐MAS (1-10 microM) for 30 hours
Number of subjects: 0
Study: 15987391

Group type: EXPERIMENTAL
Intervention: Remifentanil-based sedation regime (initial dose 6 to 9 microg kg(‐1) h(‐1) titrated to response before the addition of midazolam)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Remifentanil-based sedation regime
Number of subjects: 105

Group type: COMPARATOR
Intervention: Midazolam-based sedation regime with fentanyl or morphine
Number of subjects: 105
Study: 12500172

Group type: EXPERIMENTAL
Intervention: Surgical castration
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group with appropriate hormone levels
Number of subjects: 40
Study: 9661626

Group type: EXPERIMENTAL
Intervention: GH (12 IU/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 7814081

Group type: EXPERIMENTAL
Intervention: PGE2 gel 0.5 mg
Number of subjects: 97
Study: 3768242

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ketanserin (20 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg) plus Ketanserin (20 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30916381

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Number of subjects: 2180

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg
Number of subjects: 2180

Group type: COMPARATOR
Intervention: Control group (ADA-NEG patients)
Number of subjects: 2180
Study: 29581212

Group type: EXPERIMENTAL
Intervention: 8-week Alert Program school curriculum delivered in weekly 1-hour lessons by trained classroom teachers.
Number of subjects: 363

Group type: COMPARATOR
Intervention: Control conditions in clusters two to four (regular schooling before intervention).
Number of subjects: 363
Study: 27171822

Group type: EXPERIMENTAL
Intervention: Combined obturator nerve block (ONB) and femoral triangle block (FTB)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Single femoral triangle block (FTB)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combined ONB and FTB
Number of subjects: 75
Study: 24815544

Group type: EXPERIMENTAL
Intervention: Stand Up and Sit Less intervention
Number of subjects: 43
Study: 21628604

Group type: EXPERIMENTAL
Intervention: Asenapine 5 mg alone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Asenapine 5 mg under steady‐state valproate (500 mg bid for 9 days)
Number of subjects: 24
Study: 20642579

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT) with depigmented polymerized birch pollen extract
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 18828993

Group type: EXPERIMENTAL
Intervention: Problem-solving training (PST) via videoconferencing sessions for a year
Number of subjects: 61

Group type: COMPARATOR
Intervention: Education-only control group
Number of subjects: 61
Study: 18454251

Group type: EXPERIMENTAL
Intervention: Neurexan
Number of subjects: 409

Group type: COMPARATOR
Intervention: Valerian
Number of subjects: 409
Study: 15363875

Group type: EXPERIMENTAL
Intervention: Tenoxicam
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1001
Study: 11755507

Group type: EXPERIMENTAL
Intervention: Cholesterol lowering
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Blood pressure lowering
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intensive glucose lowering
Number of subjects: 7
Study: 9065185

Group type: EXPERIMENTAL
Intervention: Endometrial biopsy specimens obtained with a Vabra aspiration curette
Number of subjects: 2964
Study: 7681957

Group type: EXPERIMENTAL
Intervention: Early AICD implantation
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional therapeutic strategy
Number of subjects: 46
Study: 3538786

Group type: EXPERIMENTAL
Intervention: Adinazolam mesylate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 31634137

Group type: EXPERIMENTAL
Intervention: Multichannel nerve stimulation using a 2 × 8 stimulation grid on the upper arm along the ulnar and median nerves.
Number of subjects: 0
Study: 30103363

Group type: EXPERIMENTAL
Intervention: Multimodal out‐patient prevention program with recovery interventions for 12 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 58
Study: 26743539

Group type: EXPERIMENTAL
Intervention: Intravenous injection of purified Plasmodium falciparum sporozoites (n = 24)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intradermal injection of purified Plasmodium falciparum sporozoites (n = 6)
Number of subjects: 30
Study: 25629785

Group type: EXPERIMENTAL
Intervention: Balance rehabilitation and training apparatus
Number of subjects: 7
Study: 22429474

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent
Number of subjects: 695

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent
Number of subjects: 695
Study: 19149819

Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E HIV vaccine
Number of subjects: 2546

Group type: EXPERIMENTAL
Intervention: Methadone maintenance
Number of subjects: 2546

Group type: EXPERIMENTAL
Intervention: Incarceration
Number of subjects: 2546

Group type: EXPERIMENTAL
Intervention: Injecting behavior
Number of subjects: 2546

Group type: EXPERIMENTAL
Intervention: Demographic factors
Number of subjects: 2546
Study: 17495764

Group type: EXPERIMENTAL
Intervention: Oral alpha-lipoic acid (ALA) 600 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral alpha-lipoic acid (ALA) 1200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral alpha-lipoic acid (ALA) 1800 mg
Number of subjects: 0
Study: 15068403

Group type: EXPERIMENTAL
Intervention: Cyproheptadine + haloperidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol + placebo
Number of subjects: 0
Study: 11428735

Group type: EXPERIMENTAL
Intervention: Budesonide Turbuhaler 200 microg
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Budesonide Turbuhaler 400 microg
Number of subjects: 274

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study: 9870877

Group type: EXPERIMENTAL
Intervention: cA2 at 5, 10, or 20 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8066109

Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback to retrain the triceps muscle (n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional movement training (n = 8)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups (Electromyographic biofeedback and Conventional movement training)
Number of subjects: 16
Study: 3291085

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Cimetidine and Placebo
Number of subjects: 123
Study: 28707217

Group type: EXPERIMENTAL
Intervention: 1% milk (12 g carbohydrates)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: apple juice (29 g carbohydrates)
Number of subjects: 86

Group type: COMPARATOR
Intervention: water
Number of subjects: 86
Study: 27011386

Group type: EXPERIMENTAL
Intervention: Lumbrokinase DLBS1033 490 mg 3 times daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 26233677

Group type: EXPERIMENTAL
Intervention: Interactive motion-controlled games, 8 sessions over 4 weeks, average session time 26 minutes.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified in detail),
Number of subjects: 40
Study: 24256671

Group type: EXPERIMENTAL
Intervention: Platelet transfusion (one pack of apheresis platelets)
Number of subjects: 28
Study: 20843608

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test for Groups (TSST-G)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 25
Study: 18816008

Group type: EXPERIMENTAL
Intervention: Emotion-focused therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Client-centered therapy
Number of subjects: 34
Study: 17165303

Group type: EXPERIMENTAL
Intervention: Indirect resin composite
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Direct resin composite
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no tooth wear)
Number of subjects: 32
Study: 15458066

Group type: EXPERIMENTAL
Intervention: Virtual Reality Neurofeedback Training (VRNT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Virtual Reality Cognitive Training (VRCT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control Group (no training)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo Groups (desktop training)
Number of subjects: 50
Study: 10901907

Group type: EXPERIMENTAL
Intervention: Accelerated (twice daily) radiotherapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 76
Study: 8746831

Group type: EXPERIMENTAL
Intervention: Seeded grafts
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control grafts
Number of subjects: 32
Study: 2184355

Group type: EXPERIMENTAL
Intervention: Cyclosporine (4 mg per kilogram of body weight per day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 6112932

Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Innovar
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 30621702

Group type: EXPERIMENTAL
Intervention: LIPG SNPs (rs3813082, rs2000813, rs2097055, rs3819166)
Number of subjects: 2498

Group type: EXPERIMENTAL
Intervention: LIPG SNP rs2000813
Number of subjects: 2498

Group type: EXPERIMENTAL
Intervention: LIPG SNP rs2097055 and ApoA1 (rs3819166)
Number of subjects: 2498

Group type: EXPERIMENTAL
Intervention: Haplotypes (rs3813082T-rs2000813C-rs2097055T-rs3819166A)
Number of subjects: 2498

Group type: EXPERIMENTAL
Intervention: Haplotypes
Number of subjects: 2498
Study: 28238332

Group type: EXPERIMENTAL
Intervention: Silver nitrate
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Propolis
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Rhubarb extract
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Walnut extract
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 25787997

Group type: EXPERIMENTAL
Intervention: High-potassium, high-sodium meal (HKHN)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Low-potassium, high-sodium meal (LKHN)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control meal (low-potassium, low-sodium meal)
Number of subjects: 39
Study: 23866823

Group type: COMPARATOR
Intervention: 1 mg/kg benralizumab (single-dose intravenous)
Number of subjects: 27

Group type: COMPARATOR
Intervention: 100 or 200 mg benralizumab (3 monthly subcutaneous doses)
Number of subjects: 27
Study: 20883988

Group type: EXPERIMENTAL
Intervention: Loop ligation combined with vasopressin
Number of subjects: 105

Group type: COMPARATOR
Intervention: Vasopressin alone
Number of subjects: 105

Group type: COMPARATOR
Intervention: Neither loop ligation nor vasopressin
Number of subjects: 105
Study: 19587470

Group type: EXPERIMENTAL
Intervention: Baclofen sustained release (SR)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Baclofen gastro-retentive system (GRS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Baclofen immediate release (IR)
Number of subjects: 90
Study: 18001201

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (32‐33 degrees C) maintained for 48 h
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normothermia (control group)
Number of subjects: 36
Study: 15304046

Group type: EXPERIMENTAL
Intervention: Heparin (9000 IU of four heparins of different mol. wt distributions)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Activated Partial Thromboplastin Time (APTT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Endogenous Thrombin Potential (ETP)
Number of subjects: 12
Study: 11402638

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) 8 mg + Oral Contraceptive (OC)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Matched placebo (P) + Oral Contraceptive (OC)
Number of subjects: 34
Study: 9415909

Group type: EXPERIMENTAL
Intervention: Pneumatic tourniquet pressures set 50 mm above occlusion pressures
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Maximum mean pressures in upper extremity group
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Maximum mean pressures in lower extremity group
Number of subjects: 29
Study: 7904085

Group type: EXPERIMENTAL
Intervention: Combination therapy with disease-modifying antirheumatic drugs (DMARDs), specific details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 3480374

Group type: EXPERIMENTAL
Intervention: Low-fat diet (deriving 20% of energy from fat)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard diet (deriving 40% of energy from fat)
Number of subjects: 33
Study: 31126915

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 0
Study: 27641686

Group type: EXPERIMENTAL
Intervention: Positive screen for anxiety
Number of subjects: 2156

Group type: EXPERIMENTAL
Intervention: Positive screen for depression
Number of subjects: 2156

Group type: EXPERIMENTAL
Intervention: Feeling anxious item
Number of subjects: 2156

Group type: EXPERIMENTAL
Intervention: Worry item
Number of subjects: 2156
Study: 25772594

Group type: EXPERIMENTAL
Intervention: Oral calcitriol therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 35
Study: 23831920

Group type: EXPERIMENTAL
Intervention: TET2 mutated cases
Number of subjects: 100

Group type: COMPARATOR
Intervention: TET2 wild-type cases
Number of subjects: 100
Study: 21734418

Group type: EXPERIMENTAL
Intervention: Capecitabine plus docetaxel (XT)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Epirubicin plus docetaxel (ET)
Number of subjects: 68
Study: 19857636

Group type: EXPERIMENTAL
Intervention: Single-Serving
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard
Number of subjects: 19
Study: 16920898

Group type: EXPERIMENTAL
Intervention: Amlodipine besylate/atorvastatin calcium combination tablet (10/80 mg; n = 62)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Amlodipine besylate/atorvastatin calcium combination tablet (5/10 mg; n = 64)
Number of subjects: 126
Study: 15494466

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT; conjugated estrogens, 0.625 mg/d; trimonthly medroxyprogesterone acetate, 5 mg/d for 13 d)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 10932308

Group type: EXPERIMENTAL
Intervention: Purposeful activity (play activity)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Rote exercise
Number of subjects: 2
Study: 9155120

Group type: EXPERIMENTAL
Intervention: Gelseal (g-G0, n = 7)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hemashield (g-H0, n = 8)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hemashield (g-H, n = 7)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Gelseal (g-G, n = 5)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both groups (g-G and g-H)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Gelseal (g-G)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hemashield (g-H)
Number of subjects: 15
Study: 8399497

Group type: EXPERIMENTAL
Intervention: 0.5% podophyllotoxin lotion
Number of subjects: 205

Group type: COMPARATOR
Intervention: 25% podophyllin solution
Number of subjects: 205
Study: 3527643

Group type: EXPERIMENTAL
Intervention: Horse-chestnut seed extract (Venostasin retard) 600 mg (two capsules of 50 mg aescin each)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (identical-looking capsule)
Number of subjects: 22
Study: 3414574

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Vitamin A plus Iron supplementation
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 30872203

Group type: EXPERIMENTAL
Intervention: Soft-channel group
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Hard-channel group
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conservative group
Number of subjects: 150
Study: 27767387

Group type: EXPERIMENTAL
Intervention: FDIS+MET
Number of subjects: 184

Group type: COMPARATOR
Intervention: FDIS+placebo
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: SRP+MET
Number of subjects: 184

Group type: COMPARATOR
Intervention: SRP+placebo
Number of subjects: 184
Study: 25998960

Group type: EXPERIMENTAL
Intervention: Nurse Practitioner (NP) care
Number of subjects: 260

Group type: COMPARATOR
Intervention: Standard care (medical practitioner led)
Number of subjects: 260
Study: 23228571

Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei ssp. paracasei F19 (LF19) 108 colony‐forming units per serving
Number of subjects: 179

Group type: COMPARATOR
Intervention: Cereals without LF19
Number of subjects: 179
Study: 22018188

Group type: EXPERIMENTAL
Intervention: Prednisone 3 mg/day
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 19360864

Group type: EXPERIMENTAL
Intervention: Facilitated PCI with low-dose tenecteplase (10 mg)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Standard PCI (control group)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Facilitated PCI with low-dose tenecteplase
Number of subjects: 284
Study: 16297507

Group type: EXPERIMENTAL
Intervention: Vaccinated patients without systemic steroids for the previous 3 months, treated with steroids for 4 weeks
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Vaccinated patients with chronic steroid treatment both before and during the investigation
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Vaccinated patients without systemic steroids for the previous 3 months, vaccinated after 4 weeks of steroid treatment
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (not vaccinated)
Number of subjects: 49
Study: 15349684

Group type: EXPERIMENTAL
Intervention: Saucer shaped cavity and retentive grooves
Number of subjects: 550

Group type: COMPARATOR
Intervention: Dovetail retentive cavity
Number of subjects: 550
Study: 11140430

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1000 microg by inhalation via Diskhaler
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1000 microg by inhalation via Diskus
Number of subjects: 36

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 250 microg intravenously
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1000 microg twice daily via Diskhaler
Number of subjects: 36
Study: 9466099

Group type: EXPERIMENTAL
Intervention: TOF-GUARD
Number of subjects: 41

Group type: COMPARATOR
Intervention: Relaxograph
Number of subjects: 41
Study: 8402089

Group type: EXPERIMENTAL
Intervention: Novel intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional intervention
Number of subjects: 0
Study: 3652469

Group type: EXPERIMENTAL
Intervention: Progesterone (50‐100 mg/d for 7 d)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Naloxone (2 mg/h for 8 h) after progesterone treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (saline infusion)
Number of subjects: 16
Study: 31978434

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate 50 mg orally 8 hourly up to 150 mg
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 27591784

Group type: EXPERIMENTAL
Intervention: Ophthalmic artery (OA) blood flow measurement using ultrasound color doppler imaging (CDI)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Central retinal artery (CRA) blood flow measurement using ultrasound color doppler imaging (CDI)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Subgroup analysis of OA blood flow in eyes with stage I ROP, stage II ROP, and without ROP
Number of subjects: 65
Study: 26971823

Group type: EXPERIMENTAL
Intervention: Topical ethyl chloride
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (sterile water aerosol spray)
Number of subjects: 38
Study: 24387624

Group type: EXPERIMENTAL
Intervention: 60-minute loading infusion of magnesium sulphate (4 g over 60 minutes)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 20-minute loading infusion of magnesium sulphate (4 g over 20 minutes)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 60-minute loading infusion of magnesium sulphate
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 20-minute loading infusion of magnesium sulphate
Number of subjects: 51